Mylan N.V. (NASDAQ:MYL) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 26,525,497 shares, a growth of 17.0% from the August 31st total of 22,672,282 shares. Approximately 5.2% of the company’s stock are short sold. Based on an average trading volume of 6,722,873 shares, the short-interest ratio is currently 3.9 days.

Institutional investors have recently bought and sold shares of the business. Global X Management Co. LLC grew its holdings in shares of Mylan N.V. by 91.6% during the first quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock worth $118,000 after purchasing an additional 1,441 shares during the last quarter. TLP Group LLC acquired a new position in Mylan N.V. during the 1st quarter worth about $200,000. Doliver Capital Advisors LP acquired a new position in Mylan N.V. during the 2nd quarter worth about $201,000. Eagle Global Advisors LLC acquired a new position in Mylan N.V. during the 2nd quarter worth about $205,000. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in Mylan N.V. during the 2nd quarter worth about $210,000. 71.97% of the stock is currently owned by institutional investors.

Shares of Mylan N.V. (NASDAQ:MYL) opened at 32.39 on Tuesday. The firm has a market cap of $17.37 billion, a PE ratio of 26.18 and a beta of 1.30. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The company has a 50 day moving average of $31.35 and a 200-day moving average of $36.53.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. During the same quarter last year, the company earned $1.16 earnings per share. The firm’s revenue was up 15.7% on a year-over-year basis. Equities research analysts forecast that Mylan N.V. will post $4.52 EPS for the current fiscal year.

MYL has been the subject of several recent analyst reports. Cowen and Company reissued a “hold” rating and set a $30.00 price objective (down from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Wells Fargo & Company set a $30.00 target price on shares of Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan N.V. and gave the company a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $32.00 price target (down previously from $33.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Finally, ValuEngine raised shares of Mylan N.V. from a “hold” rating to a “buy” rating in a research report on Monday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Mylan N.V. has an average rating of “Buy” and an average target price of $42.46.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/03/short-interest-in-mylan-n-v-myl-rises-by-17-0.html.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.